STI571

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Systemic Sclerosis, Scleroderma

Conditions

Systemic Sclerosis, Scleroderma

Trial Timeline

Jan 2, 2008 → Jan 13, 2010

NCT ID

NCT00613171

About STI571

STI571 is a phase 2 stage product being developed by Novartis for Systemic Sclerosis, Scleroderma. The current trial status is completed. This product is registered under clinical trial identifier NCT00613171. Target conditions include Systemic Sclerosis, Scleroderma.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Sclerosis, Scleroderma were approved

Approved (10) Terminated (4) Active (7)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00613171	Phase 2	Completed	Jan 2, 2008	Jan 13, 2010	Systemic Sclerosis, Scleroderma
NCT00276926	Phase 2	UNKNOWN	Mar 1, 2003	—	Hypereosinophilic Syndrome
NCT00511303	Phase 2	Completed	Aug 1, 2000	—	Chronic Myeloid Leukemia
NCT00171223	Phase 2	Completed	Dec 6, 1999	Nov 29, 2013	Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Competing Products

20 competing products in Systemic Sclerosis, Scleroderma

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29